(PDF) Phase II Clinical Trial of Adoptive Cell Therapy for

Phase II Clinical Trial of Adoptive Cell Therapy for Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Low-Dose Interleukin-2

Cancer Immunology, Immunotherapy - Germany

doi 10.1007/s00262-019-02307-x

Full Text

Open PDF

Abstract

Available in full text

Date

February 11, 2019

Authors

Publisher

Springer Science and Business Media LLC

Amanote Research

Phase II Clinical Trial of Adoptive Cell Therapy for Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Low-Dose Interleukin-2

Cancer Immunology, Immunotherapy - Germany

doi 10.1007/s00262-019-02307-x

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Minimally Invasive Liver Resection to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy in Patients With Metastatic Melanoma

Efficacy of Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma

Treatment With Tumour Infiltrating Lymphocytes and Interleukin-2 in Patients With Metastatic Melanoma: A Pilot Study

Adoptive Immunotherapy With Tumor-Infiltrating Lymphocytes Against Metastatic Liver Tumors.

A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma

Phase I/Ii Trial of Melanoma Therapy With Dendritic Cells Transfected With Autologous Tumor-mRNA

Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma

Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-Dendritic Cell Vaccine With Aldesleukin (Interleukin 2) and IFN- 2a Therapy in Metastatic Renal Cell Carcinoma Patients

A Multi-Center Phase II Study of High Dose Interleukin-2 Sequenced With Vemurafenib in Patients With BRAF-V600 Mutation Positive Metastatic Melanoma